What are Anti-IgE monoclonal antibody drugs?

Anti-IgE monoclonal antibody drugs are pharmacologic agents that share a common mechanism (typically targeting Immunoglobulin E (IgE)). 4 are currently marketed, with 2 more in clinical development.

What are the marketed Anti-IgE monoclonal antibody drugs?

Marketed Anti-IgE monoclonal antibody drugs include ANTI-IGE THERAPY (XOLAIR), Xolair injections, Omalizumab Injection, Omalizumab (Xolair).

Anti-IgE monoclonal antibody

4 marketed 2 in Phase 3

This page covers all Anti-IgE monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Immunoglobulin E (IgE).

Targets

Immunoglobulin E (IgE)

Marketed (4)

ANTI-IGE THERAPY (XOLAIR) · Children's Hospital of The King's Daughters · Immunology / Allergy / Respiratory
Xolair (omalizumab) is a monoclonal antibody that binds to circulating IgE, preventing it from interacting with high-affinity IgE receptors on mast cells and basophils.
Xolair injections · University of California, Los Angeles · Immunology / Allergy
Xolair is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing it from interacting with high-affinity IgE receptors on mast cells and basophils.
Omalizumab Injection · Rigshospitalet, Denmark · Immunology / Allergy / Respiratory
Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing IgE from interacting with high-affinity IgE receptors on mast cells and basophils.
Omalizumab (Xolair) · McMaster University · Immunology / Allergy
Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing IgE from interacting with high-affinity IgE receptors on mast cells and basophils.

Phase 3 pipeline (2)

Omalizumab (CinnaGen) · Cinnagen · Immunology / Allergy
Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing its interaction with high-affinity IgE receptors on mast cells and basophils.
EU-approved Xolair · Celltrion · Immunology / Allergy
Xolair is a monoclonal antibody that binds to immunoglobulin E (IgE) and prevents its interaction with high-affinity IgE receptors on mast cells and basophils, thereby reducing allergic cascade activation.